Business Context and Reporting Period
Company: Liminatus Pharma, Inc. (LIMN)
Filing Type: Form 8-K (Current Report)
Date of Report: June 3, 2026
Reporting Period: Event-based (June 3, 2026)
Context: The Company, an emerging growth company, entered into a warrant exercise inducement agreement to facilitate the exercise of existing warrants and raise capital for working capital and general corporate purposes.
Key Financial Metrics
- Gross Proceeds: Approximately $1,861,920 from the exercise of existing warrants.
- Transaction Fees: Cash fee of up to 8% of gross proceeds payable to Maxim Group LLC.
- Exercise Price (Existing Warrants): Reduced to $0.18 per share.
- Shares Issued (Existing): 10,344,000 shares of common stock.
- Shares Underlying New Warrants: Up to 20,688,000 shares (10,344,000 Black-Scholes Warrants + 10,344,000 Change of Control Warrants).
- Exercise Price (New Warrants): $0.18 per share.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, margins, or total debt.
Material Changes
The primary material change is the modification of rights for security holders regarding existing warrants and the issuance of new unregistered securities:
- Warrant Modification: Existing warrants exercisable for 10,344,000 shares were modified to allow exercise at a reduced price of $0.18 per share.
- New Issuance: Issuance of 20,688,000 new warrants (Inducement Warrants) in a private placement under Section 4(a)(2) of the Securities Act.
- Registration: The Company agreed to file a resale registration statement on Form S-3 within 20 calendar days of closing.
Outlook, Risks, and Contingencies
- Use of Proceeds: Net proceeds will be used for working capital and general corporate purposes.
- Contingencies: The Inducement Warrants are exercisable only after obtaining stockholder approval for the exercise and, if necessary, authorization for additional shares. This approval must be obtained at a meeting of stockholders.
- Term: The Inducement Warrants will be exercisable for five years from the "Exercise Date" (date of stockholder approval).
- Risks: The new warrants and underlying shares are unregistered and may not be offered or sold in the U.S. except pursuant to an effective registration statement or exemption.
Investor Verification Checklist
- Verify the status of the stockholder meeting required to approve the exercise of the Inducement Warrants.
- Confirm the filing of the Form S-3 resale registration statement within the 20-day window.
- Review the full text of the Inducement Letter Agreement (Exhibit 10.1) for specific terms regarding the 8% advisory fee and any other conditions.
- Assess the dilution impact of the potential issuance of 20,688,000 new shares upon exercise of the Inducement Warrants.
- Check the Company's current cash position to determine the sufficiency of the $1.86 million gross proceeds for stated working capital needs.